BCL2L11 and acute lymphoblastic leukemia: Since BIM is required for GC-induced apoptosis in lymphoid lineage cells, including ALL cells [26]–[32], and both in vitro and in vivo GC response has been shown to predict favorable treatment outcome in ALL [33]–[37], we wondered if the polymorphism could contribute to response heterogeneity in ALL patients.